Drug Trial Radar · NCT06122012
To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China
Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
136
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Apr 30, 2024
Study completion May 2024
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Observe the effects of HSK16149 capsule combined with acetyl-L-carnitine hydrochloride tablets and lipoic acid combined with acetyl-L-carnitine hydrochloride tablets Efficacy and safety in diabetic peripheral neuralgia patients in China
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
HSK16149 20mg BIDDrug
HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ;Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID;
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the efficacy and safety of HSK16149 capsule combined with acetyl-L-carnitine hydrochloride tablet and lipoic acid combined with acetyl-L-carnitine hydrochloride tablet in the treatment of diabetic peripheral neuralgiaTime frame: week12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.